Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.

ParinGenix Inc. is currently developing a modified form of the widely used anticoagulant, heparin, to treat cardiac ischemia-reperfusion injury following myocardial infarction.

Ischemia-induced damage isn't the only harmful effect of heart attacks, and a number of recently founded companies are investigating new mechanisms to protect the heart.